Neurocrine Biosciences Files Soleno 2025 Audited Financials

What Happened
Neurocrine Biosciences (NBIX) filed an 8-K on July 31, 2026 amending a prior report to include the audited consolidated financial statements of Soleno (as defined in the Original Report) for the year ended December 31, 2025 and the unaudited interim condensed consolidated financial statements of Soleno for the three months ended March 31, 2026. The amendment also updates information contained in the Original Report.

Key Details

• Filing date: July 31, 2026 (8-K amendment under Item 9.01: Financial Statements and Exhibits).
• Audited statements added: Consolidated financial statements of Soleno for year ended Dec 31, 2025.
• Interim statements added: Unaudited interim condensed consolidated financial statements for the three months ended Mar 31, 2026.
• Soleno is the entity referenced in the Original Report; the filing supplements that prior disclosure.

Why It Matters
These newly filed audited and interim financial statements give investors concrete, audited historical and recent quarterly financial information about Soleno that was previously not included in the Original Report. That information is important for evaluating the financial condition and recent results of Soleno and for assessing any disclosed transaction or relationship between Soleno and Neurocrine (as described in the Original Report). The filing improves disclosure transparency and compliance with SEC reporting requirements.